139 related articles for article (PubMed ID: 27080364)
21. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
22. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.
Bellón T; Lerma V; González-Valle O; González Herrada C; de Abajo FJ
Br J Dermatol; 2016 Mar; 174(3):621-4. PubMed ID: 26412570
[TBL] [Abstract][Full Text] [Related]
23. Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test.
Seremet T; Haccuria A; Lienard D; Del Marmol V; Neyns B
Melanoma Res; 2019 Feb; 29(1):95-98. PubMed ID: 30383722
[TBL] [Abstract][Full Text] [Related]
24. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
25. Dabrafenib-associated necrobiotic granulomatous reaction.
Carlos G; Anforth R; Chou S; Fernandez-Peñas P
Australas J Dermatol; 2014 Nov; 55(4):306-8. PubMed ID: 25399793
[No Abstract] [Full Text] [Related]
26. BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome.
Perico L; Mandalà M; Schieppati A; Carrara C; Rizzo P; Conti S; Longaretti L; Benigni A; Remuzzi G
Am J Kidney Dis; 2017 Jul; 70(1):145-150. PubMed ID: 28242136
[TBL] [Abstract][Full Text] [Related]
27. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity.
Adelmann CH; Ching G; Du L; Saporito RC; Bansal V; Pence LJ; Liang R; Lee W; Tsai KY
Oncotarget; 2016 May; 7(21):30453-60. PubMed ID: 27028853
[TBL] [Abstract][Full Text] [Related]
28. [Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].
Heneberg P
Klin Onkol; 2012; 25(5):333-9. PubMed ID: 23102194
[TBL] [Abstract][Full Text] [Related]
29. Recurrent tattoo reactions in a patient treated with BRAF and MEK inhibitors.
Reinhard R; Gebhardt C; Schmieder A; Umansky V; Utikal J
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e375-e377. PubMed ID: 28222227
[No Abstract] [Full Text] [Related]
30. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
31. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
[TBL] [Abstract][Full Text] [Related]
32. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
33. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
34. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
Planchard D; Kim TM; Mazieres J; Quoix E; Riely G; Barlesi F; Souquet PJ; Smit EF; Groen HJ; Kelly RJ; Cho BC; Socinski MA; Pandite L; Nase C; Ma B; D'Amelio A; Mookerjee B; Curtis CM; Johnson BE
Lancet Oncol; 2016 May; 17(5):642-50. PubMed ID: 27080216
[TBL] [Abstract][Full Text] [Related]
35. Dabrafenib therapy for advanced melanoma.
Trinh VA; Davis JE; Anderson JE; Kim KB
Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661
[TBL] [Abstract][Full Text] [Related]
36. Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?
Sloot S; Fedorenko IV; Smalley KS; Gibney GT
Expert Opin Pharmacother; 2014 Apr; 15(5):589-92. PubMed ID: 24456413
[TBL] [Abstract][Full Text] [Related]
37. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
[TBL] [Abstract][Full Text] [Related]
38. Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab.
Choi JN
Semin Cutan Med Surg; 2014 Mar; 33(1):40-8. PubMed ID: 25037257
[TBL] [Abstract][Full Text] [Related]
39. New RAF kinase inhibitors in cancer therapy.
Martin-Liberal J; Larkin J
Expert Opin Pharmacother; 2014 Jun; 15(9):1235-45. PubMed ID: 24766074
[TBL] [Abstract][Full Text] [Related]
40. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
Queirolo P; Picasso V; Spagnolo F
Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
